NEO100 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-30 in 3mo
ESTIMATED |
READOUT
NEO100 and High-Grade Meningioma
Phase 2 · Residual, Progressive or Recurrent Grade II or III Meningioma |
NTHI NEONC TECHNOLOGIES HOLDINGS, | NEO100 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|